NL192562C - Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. - Google Patents

Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. Download PDF

Info

Publication number: NL192562C
Authority: NL; Netherlands
Prior art keywords: mineralization; reabsorption; bone; amino; ahbubp
Prior art date: 1982-04-15

Application number

NL8301324A

Other languages

English (en)

Dutch (nl)

Other versions

NL192562B (nl

NL8301324A (nl

Original Assignee

Gentili Ist Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-15

Filing date

1983-04-15

Publication date

1997-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11171970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL192562(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1983-04-15 Application filed by Gentili Ist Spa filed Critical Gentili Ist Spa

1983-11-01 Publication of NL8301324A publication Critical patent/NL8301324A/nl

1997-06-02 Publication of NL192562B publication Critical patent/NL192562B/xx

1997-10-03 Application granted granted Critical

1997-10-03 Publication of NL192562C publication Critical patent/NL192562C/nl

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 8
-1 2OH compound Chemical class 0.000 title claims description 7
150000001875 compounds Chemical class 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 20
230000009103 reabsorption Effects 0.000 claims description 14
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 13
210000000988 bone and bone Anatomy 0.000 claims description 12
229940122361 Bisphosphonate Drugs 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
150000004663 bisphosphonates Chemical class 0.000 claims description 10
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 claims description 10
230000033558 biomineral tissue development Effects 0.000 claims description 9
230000005764 inhibitory process Effects 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
208000020084 Bone disease Diseases 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
239000013078 crystal Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
150000001413 amino acids Chemical class 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
230000007059 acute toxicity Effects 0.000 claims description 3
231100000403 acute toxicity Toxicity 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
150000007530 organic bases Chemical class 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
231100000331 toxic Toxicity 0.000 claims description 2
230000002588 toxic effect Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims 3
230000018678 bone mineralization Effects 0.000 claims 2
230000004821 effect on bone Effects 0.000 claims 2
BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 claims 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
229920002472 Starch Polymers 0.000 claims 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
229930006000 Sucrose Natural products 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
239000002775 capsule Substances 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
239000001913 cellulose Substances 0.000 claims 1
229920002678 cellulose Polymers 0.000 claims 1
235000014113 dietary fatty acids Nutrition 0.000 claims 1
239000000194 fatty acid Substances 0.000 claims 1
229930195729 fatty acid Natural products 0.000 claims 1
150000004665 fatty acids Chemical class 0.000 claims 1
239000008103 glucose Substances 0.000 claims 1
239000008101 lactose Substances 0.000 claims 1
239000008107 starch Substances 0.000 claims 1
235000019698 starch Nutrition 0.000 claims 1
239000005720 sucrose Substances 0.000 claims 1
235000000346 sugar Nutrition 0.000 claims 1
150000005846 sugar alcohols Polymers 0.000 claims 1
150000008163 sugars Chemical class 0.000 claims 1
238000007910 systemic administration Methods 0.000 claims 1
239000000454 talc Substances 0.000 claims 1
229910052623 talc Inorganic materials 0.000 claims 1
231100000419 toxicity Toxicity 0.000 claims 1
230000001988 toxicity Effects 0.000 claims 1
210000004027 cell Anatomy 0.000 description 19
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 16
229940046231 pamidronate Drugs 0.000 description 14
239000000243 solution Substances 0.000 description 11
241001465754 Metazoa Species 0.000 description 9
239000011575 calcium Substances 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
238000000034 method Methods 0.000 description 7
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 6
229960002286 clodronic acid Drugs 0.000 description 6
229940009626 etidronate Drugs 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000000536 complexating effect Effects 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
208000001132 Osteoporosis Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 3
230000008859 change Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
229910001385 heavy metal Inorganic materials 0.000 description 3
239000000463 material Substances 0.000 description 3
210000003625 skull Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
DXGBLRMRXHGUFX-UHFFFAOYSA-N (5-amino-1-hydroxy-1-phosphonopentyl)phosphonic acid Chemical compound NCCCCC(O)(P(O)(O)=O)P(O)(O)=O DXGBLRMRXHGUFX-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
WCJADIUJTZRJKN-UHFFFAOYSA-N ClCCl.OP(O)=O.OP(O)=O Chemical compound ClCCl.OP(O)=O.OP(O)=O WCJADIUJTZRJKN-UHFFFAOYSA-N 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
QVURYMLMERKPNC-UHFFFAOYSA-N FCF.OP(O)=O.OP(O)=O Chemical compound FCF.OP(O)=O.OP(O)=O QVURYMLMERKPNC-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
230000002308 calcification Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
238000003926 complexometric titration Methods 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 2
125000004437 phosphorous atom Chemical group 0.000 description 2
238000003918 potentiometric titration Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000011343 solid material Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
210000002303 tibia Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
RUPZRJCPTQGQRU-UHFFFAOYSA-N (1-hydroxy-1-phosphonobutyl)phosphonic acid Chemical compound CCCC(O)(P(O)(O)=O)P(O)(O)=O RUPZRJCPTQGQRU-UHFFFAOYSA-N 0.000 description 1
LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229910018828 PO3H2 Inorganic materials 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
QAOWNCQODCNURD-ZSJDYOACSA-N Sulfuric acid-d2 Chemical compound [2H]OS(=O)(=O)O[2H] QAOWNCQODCNURD-ZSJDYOACSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229940124605 anti-osteoporosis drug Drugs 0.000 description 1
229910052586 apatite Inorganic materials 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
230000000544 hyperemic effect Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229910052816 inorganic phosphate Inorganic materials 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000011164 ossification Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
VGBPIHVLVSGJGR-UHFFFAOYSA-N thorium(4+);tetranitrate Chemical compound [Th+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VGBPIHVLVSGJGR-UHFFFAOYSA-N 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
235000005282 vitamin D3 Nutrition 0.000 description 1
239000011647 vitamin D3 Substances 0.000 description 1
229940021056 vitamin d3 Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8301324A 1982-04-15 1983-04-15 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat. NL192562C (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2078182		1982-04-15
IT8220781A IT1201087B (it)	1982-04-15	1982-04-15	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche

Publications (3)

Publication Number	Publication Date
NL8301324A NL8301324A (nl)	1983-11-01
NL192562B NL192562B (nl)	1997-06-02
NL192562C true NL192562C (nl)	1997-10-03

Family

ID=11171970

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
NL8301324A NL192562C (nl)	1982-04-15	1983-04-15	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL970038C NL970038I2 (nl)	1982-04-15	1997-11-07	Farmaceutisch preparaat dat een NH2-(CH2)3-C(P03H2)2OH-verbinding bevat.
NL980004C NL980004I1 (nl)	1982-04-15	1998-01-09	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980005C NL980005I1 (nl)	1982-04-15	1998-01-26	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980010C NL980010I1 (nl)	1982-04-15	1998-03-03	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
NL970038C NL970038I2 (nl)	1982-04-15	1997-11-07	Farmaceutisch preparaat dat een NH2-(CH2)3-C(P03H2)2OH-verbinding bevat.
NL980004C NL980004I1 (nl)	1982-04-15	1998-01-09	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980005C NL980005I1 (nl)	1982-04-15	1998-01-26	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980010C NL980010I1 (nl)	1982-04-15	1998-03-03	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.

Country Status (12)

Country	Link
US (1)	US4621077A (it)
JP (1)	JPS58189193A (it)
BE (1)	BE896453A (it)
CH (1)	CH661437A5 (it)
FR (1)	FR2525223B1 (it)
GB (1)	GB2118042B (it)
HK (1)	HK79390A (it)
IT (1)	IT1201087B (it)
LU (2)	LU84746A1 (it)
MX (1)	MX9203428A (it)
NL (5)	NL192562C (it)
SE (1)	SE463239B (it)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8419489D0 (en) *	1984-07-31	1984-09-05	Leo Pharm Prod Ltd	Chemical compounds
IL77243A (en) *	1984-12-21	1996-11-14	Procter & Gamble	Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) *	1985-04-06	1986-10-16	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) *	1985-11-13	1987-05-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) *	1986-07-11	1988-01-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL86951A (en) *	1987-07-06	1996-07-23	Procter & Gamble Pharma	Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4963681A (en) *	1987-07-06	1990-10-16	Norwich Eaton Pharmaceuticals, Inc.	Process for synthesis of aminomethylene phosphonoalkylphosphinates
US4922007A (en) *	1989-06-09	1990-05-01	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) *	1989-09-06	1993-07-13	Merck & Co., Inc.	Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI83657C (fi) *	1989-09-08	1991-08-12	Huhtamaeki Oy	Foerfarande foer framstaellning av metylenbisfosfonsyror.
US5356887A (en) *	1990-01-31	1994-10-18	Merck & Co., Inc.	Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) *	1990-06-20	1991-05-28	Merck & Co., Inc.	Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
GB2248061A (en) *	1990-09-18	1992-03-25	Merck & Co Inc	Amino-hydroxy-alkylidene bis phosphonic acids
US5183815A (en) *	1991-01-22	1993-02-02	Merck & Co., Inc.	Bone acting agents
IT1247034B (it) *	1991-06-26	1994-12-12	Gentili Ist Spa	Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
US6096342A (en) *	1997-03-12	2000-08-01	The Procter & Gamble Company	Dosage forms of risedronate
US5270365A (en) *	1991-12-17	1993-12-14	Merck & Co., Inc.	Prevention and treatment of periodontal disease with alendronate
TW237386B (it) *	1992-04-15	1995-01-01	Ciba Geigy
US5358941A (en)	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en)	1992-12-02	2002-06-18	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids
US6399592B1 (en)	1992-12-23	2002-06-04	Merck & Co., Inc.	Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) *	1993-10-12	1997-01-07	The Regents Of The University Of California	Inhibition of urinary calculi growth
US5854227A (en) *	1994-03-04	1998-12-29	Hartmann; John F.	Therapeutic derivatives of diphosphonates
US20010007863A1 (en) *	1998-06-18	2001-07-12	Merck & Co., Inc.	Wet granulation formulation for bisphosphonic acids
US5449819A (en) *	1994-06-06	1995-09-12	Merck & Co., Inc.	Process for removing waste pox, alendronate and its by products
US6008206A (en) *	1994-09-21	1999-12-28	Merck & Co., Inc.	Sodium alendronate preparation for local administration
JP3411690B2 (ja) *	1994-09-21	2003-06-03	帝人株式会社	局所投与用アレンドロン酸ナトリウム製剤
WO1996025165A1 (en) *	1995-02-17	1996-08-22	Merck & Co., Inc.	Method of lessening the risk of non-vertebral bone fractures
US20010051616A1 (en) *	1995-02-17	2001-12-13	David B. Karpf	Method of lessening the risk of vertebral fractures
AU713824B2 (en) *	1995-05-12	1999-12-09	Merck Sharp & Dohme Corp.	Prevention of tooth loss by the administration of alendronate or its salts
WO1996039410A1 (en) *	1995-06-06	1996-12-12	Merck & Co., Inc.	Disodium alendronate formulations
DK0833643T3 (da) *	1995-06-06	2005-05-30	Merck & Co Inc	Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
EP0831756A1 (en)	1995-06-06	1998-04-01	Merck & Co., Inc.	Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
EP1378234A1 (en) *	1996-05-17	2004-01-07	MERCK & CO. INC.	Effervescent bisphosphonate formulation
EP0939624B1 (en) *	1996-05-17	2003-12-17	Merck & Co., Inc.	Effervescent bisphosphonate formulation
EP1820497A3 (en) *	1996-05-17	2009-07-22	Merck & Co., Inc.	Effervescent bisphosphonate formulation
NZ334836A (en) *	1996-10-04	2000-11-24	Merck & Co Inc	Liquid alendronate formulations and their use in preventing bone resorption
US6376477B2 (en)	1996-11-25	2002-04-23	Merck & Co., Inc.	Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
US6410782B1 (en)	1997-07-09	2002-06-25	Geange Ltd.	Diphosphonic acid salts for the treatment of osteoporosis
US6432932B1 (en)	1997-07-22	2002-08-13	Merck & Co., Inc.	Method for inhibiting bone resorption
US5994329A (en) *	1997-07-22	1999-11-30	Merck & Co., Inc.	Method for inhibiting bone resorption
US6416964B2 (en)	1998-01-29	2002-07-09	Merck & Co., Inc.	Methods of identifying modulators of kinases responsive to stress
US6750340B2 (en)	1998-04-02	2004-06-15	Mbc Research, Inc.	Bisphosphonate conjugates and methods of making and using the same
US6896871B2 (en)	1998-04-02	2005-05-24	Mbc Research, Inc.	Biphosphonate conjugates and methods of making and using the same
US7598246B2 (en) *	1998-04-02	2009-10-06	Mbc Pharma, Inc.	Bisphosphonate conjugates and methods of making and using the same
US6214812B1 (en) *	1998-04-02	2001-04-10	Mbc Research, Inc.	Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en)	1998-04-02	2013-11-19	Mbc Pharma, Inc.	Bone targeted therapeutics and methods of making and using the same
US20030078211A1 (en) *	1998-06-24	2003-04-24	Merck & Co., Inc.	Compositions and methods for inhibiting bone resorption
CA2336201A1 (en)	1998-06-24	1999-12-29	Merck & Co., Inc.	Compositions and methods for inhibiting bone resorption
US6008207A (en) *	1998-08-13	1999-12-28	Merck & Co., Inc.	Anhydrous alendronate monosodium salt formulations
SI20581B (sl)	1998-08-27	2008-06-30	Teva Pharma	Nove hidratne oblike natrijevega alendronata, postopki za njihovo pridobivanje in ustrezne farmacevtske učinkovine
US6331533B1 (en)	1998-11-16	2001-12-18	Merck & Co., Inc.	Method for inhibiting dental resorptive lesions
AU770312B2 (en) *	1999-02-17	2004-02-19	Teva Pharmaceutical Industries Ltd.	Novel process for preparing alendronic acid
US7205404B1 (en)	1999-03-05	2007-04-17	Metabasis Therapeutics, Inc.	Phosphorus-containing prodrugs
AR024462A1 (es)	1999-07-01	2002-10-02	Merck & Co Inc	Tabletas farmaceuticas
SE9903345D0 (sv) *	1999-09-17	1999-09-17	Astra Pharma Prod	Novel process
AR021347A1 (es) *	1999-10-20	2002-07-17	Cipla Ltd	Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
KR100317935B1 (ko) *	1999-10-20	2001-12-22	유승필	대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6677320B2 (en)	2000-01-20	2004-01-13	Hoffmann-La Roches Inc.	Parenteral bisphosphonate composition with improved local tolerance
US6410520B2 (en)	2000-02-01	2002-06-25	The Procter & Gamble Company	Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
PE20011065A1 (es)	2000-02-01	2001-11-21	Procter & Gamble	Proceso para fabricar bisfosfonatos geminales
US6468559B1 (en)	2000-04-28	2002-10-22	Lipocine, Inc.	Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6476006B2 (en)	2000-06-23	2002-11-05	Teva Pharmaceutical Industries, Ltd.	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6638920B2 (en) *	2000-07-21	2003-10-28	Merck & Co., Inc.	Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20040038946A1 (en) *	2001-04-27	2004-02-26	Wilson Lon J.	Fullerene-based drugs targeted to bone
ES2268086T3 (es) *	2001-05-02	2007-03-16	Novartis Ag	Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
US20030216358A1 (en) *	2001-07-05	2003-11-20	Muchmore Douglas Boyer	Method for enhancing bone mineral density gain
US20050070504A1 (en) *	2001-12-21	2005-03-31	The Procter & Gamble Co.	Risedronate compositions and their methods of use
CZ2004690A3 (cs) *	2001-12-21	2004-09-15	The Procter & Gamble Company	Souprava a způsob jejího použití k léčbě kostních chorob
JP4625637B2 (ja)	2002-02-22	2011-02-02	シャイアエルエルシー	活性物質送達系及び活性物質を保護し投与する方法
US7488496B2 (en) *	2002-03-06	2009-02-10	Christer Rosen	Effervescent compositions comprising bisphosphonates and methods related thereto
CA2480814A1 (en) *	2002-04-05	2003-10-23	Merck & Co., Inc.	Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ITMI20020908A1 (it) *	2002-04-29	2003-10-29	Chemi Spa	Processo di preparazione di sodio alendronato
KR20090106663A (ko)	2002-05-10	2009-10-09	에프. 호프만-라 로슈 아게	골다공증 치료 및 예방용 비스포스폰산
EP1476451B1 (en) *	2002-05-17	2010-03-17	Teva Pharmaceutical Industries Ltd.	Use of certain diluents for making bisphosphonic acids
US20040137058A1 (en) *	2002-07-09	2004-07-15	Katdare Ashok V.	Effervescent bisphosphonate formulation
US20040138180A1 (en) *	2002-10-03	2004-07-15	Barr Laboratories, Inc.	Bisphosphonate composition and process for the preparation thereof
EP1596870B2 (en) *	2002-12-20	2011-04-06	F. Hoffmann-La Roche AG	High dose ibandronate formulation
US20040206932A1 (en) *	2002-12-30	2004-10-21	Abuelyaman Ahmed S.	Compositions including polymerizable bisphosphonic acids and methods
CN1325506C (zh) *	2003-05-15	2007-07-11	中国科学院上海药物研究所	骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
EP2279722B1 (en) *	2003-08-12	2013-05-01	3M Innovative Properties Company	Self-etching dental compositions and its use
NZ545804A (en) *	2003-09-19	2009-09-25	Wisconsin Alumni Res Found	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
US20050181043A1 (en) *	2004-02-12	2005-08-18	Indranil Nandi	Alendronate salt tablet compositions
US20050261250A1 (en) *	2004-05-19	2005-11-24	Merck & Co., Inc.,	Compositions and methods for inhibiting bone resorption
CN1956706A (zh)	2004-05-24	2007-05-02	宝洁公司	包含一种螯合剂的双膦酸酯肠溶固体口服剂型
KR100564628B1 (ko) *	2004-06-16	2006-03-28	삼성전자주식회사	스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
WO2006014597A1 (en)	2004-07-08	2006-02-09	3M Innovative Properties Company	Dental methods, compositions, and kits including acid-sensitive dyes
CA2575976A1 (en)	2004-08-11	2006-02-23	3M Innovative Properties Company	Self-adhesive compositions including a plurality of acidic compounds
WO2007109585A2 (en) *	2006-03-17	2007-09-27	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods
US8012949B2 (en) *	2004-10-08	2011-09-06	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (en) *	2004-10-08	2006-04-13	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
CN1304401C (zh) *	2004-12-28	2007-03-14	浙江工业大学	一种阿伦膦酸的制备方法
KR20070121759A (ko) *	2005-03-17	2007-12-27	엘란 파마 인터내셔널 리미티드	나노입자형 비스포스포네이트 조성물
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
US20070087052A1 (en) *	2005-10-19	2007-04-19	Katdare Ashok V	Effervescent bisphosphonate formulation
WO2007101415A2 (de)	2006-02-03	2007-09-13	Universität Stuttgart - Institut für Chemische Verfahrenstechnik	Phosphonsäure-haltige blends und phosphonsäure-haltige polymere
JP2010510230A (ja) *	2006-11-21	2010-04-02	テイコクファーマユーエスエーインコーポレーテッド	ビスホスホネート吸入剤及びその使用方法
JP5507256B2 (ja)	2006-12-13	2014-05-28	スリーエムイノベイティブプロパティズカンパニー	酸性成分及び光退色性染料を有する歯科用組成物の使用方法
US20080182823A1 (en) *	2007-01-26	2008-07-31	Hidesmasa Katsumi	Polymer-linked-biophosphonate inhalant formulations and methods for using the same
AU2008350907A1 (en)	2007-12-11	2009-08-27	Viamet Pharmaceuticals, Inc.	Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2240159A2 (en) *	2008-02-05	2010-10-20	Actavis Group PTC EHF	Alendronate formulations, method of making and method of use thereof
US7964584B2 (en) *	2008-08-01	2011-06-21	Dong Wha Pharmaceutical Co., Ltd.	Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100034752A1 (en) *	2008-08-11	2010-02-11	Toru Hibi	Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
FR2954320B1 (fr)	2009-12-17	2012-06-15	Cll Pharma	Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
RU2640582C2 (ru)	2011-08-01	2018-01-10	Мбс Фарма, Инк.	Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов
GB201200868D0 (en)	2012-01-19	2012-02-29	Depuy Int Ltd	Bone filler composition
JP2017512183A (ja)	2014-02-13	2017-05-18	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
PL407922A1 (pl)	2014-04-16	2015-10-26	Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością	Nowe bisfosfoniany i ich zastosowanie
EP3164136A4 (en)	2014-07-02	2018-04-04	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
RU2020126177A (ru)	2018-01-09	2022-02-10	Лиганд Фармасьютикалз, Инк.	Ацетальные соединения и их терапевтическое применение

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1143123A (en) *	1966-05-18	1969-02-19	Albright & Wilson Mfg Ltd	Phosphate compositions
GB1235029A (en) *	1966-12-29	1971-06-09	Procter & Gamble	Stannous polyphosphonates and their use in oral compositions for caries prophylaxis
PH9776A (en) *	1967-12-11	1976-03-17	M Francis	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3683080A (en) *	1970-08-28	1972-08-08	Procter & Gamble	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
PH9853A (en) *	1972-06-08	1976-04-13	M Francis	Compositions for inhibiting mobilization of calcium phosphate in animal tissue and method of use thereof
IE37842B1 (en) *	1972-06-30	1977-10-26	Procter & Gamble	Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
CA1028246A (en) *	1973-05-23	1978-03-21	The Procter And Gamble Company	Compositions for the treatment of calcific tumors
DE2405254C2 (de) *	1974-02-04	1982-05-27	Henkel KGaA, 4000 Düsseldorf	Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US3987157A (en) *	1974-08-29	1976-10-19	Union Carbide Corporation	Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
DE2534391C2 (de) *	1975-08-01	1983-01-13	Henkel KGaA, 4000 Düsseldorf	1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) *	1975-12-01	1977-07-13	Henkel & Cie Gmbh	Medicine for treating metabolic obstruction of calcium
US4137309A (en) *	1976-10-14	1979-01-30	The Procter & Gamble Company	Therapeutic treatment
US4275059A (en) *	1977-03-28	1981-06-23	The Procter & Gamble Company	Salicylate anti-inflammatory composition
US4216211A (en) *	1977-10-31	1980-08-05	The Procter & Gamble Company	Therapeutic composition
US4230700A (en) *	1977-12-07	1980-10-28	The Procter & Gamble Company	Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330537A (en) *	1977-12-07	1982-05-18	The Procter & Gamble Company	Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4216212A (en) *	1978-06-08	1980-08-05	The Procter & Gamble Company	Pyrazolidine anti-inflammatory composition and methods of use
IT1097292B (it) *	1978-06-27	1985-08-31	Gentili Ist Spa	Composizione farmaceutica per la terapia dell'ittero ostruttivo non neoplastico
US4282214A (en) *	1978-07-31	1981-08-04	The Procter & Gamble Company	Phenylacetate anti-inflammatory composition
US4264582A (en) *	1978-07-31	1981-04-28	The Procter & Gamble Company	Isobutylphenylacetate anti-inflammatory composition
US4254114A (en) *	1979-01-02	1981-03-03	The Proctor & Gamble Company	Control of pyrophosphate microorganisms with organophosphonates
GB2043072B (en) *	1979-02-13	1983-11-23	Symphar Sa	Diphosphonate compounds
GB2076889B (en) *	1980-03-12	1983-10-26	Cadbury Schweppes Transport	Feeding fuel and water emulsion i c engines
DE3016289A1 (de) *	1980-04-28	1981-10-29	Henkel KGaA, 4000 Düsseldorf	Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
GB2079285B (en) *	1980-07-09	1984-05-23	Symphar Sa	Dipthosphonate derivatives and pahrmaceutical compositions containing them
GB2082585A (en) *	1980-08-27	1982-03-10	Vysoka Skola Chem Tech	6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
JPS5759900A (en) *	1980-09-29	1982-04-10	Vysoka Skola Chem Tech	6-amino-1-hydroxyhexylidene diphosphonic acid
BE890453A (fr) *	1980-10-07	1982-03-22	Procter & Gamble	Procede d'inhibition des metastases de cellules tumorales
US4330530A (en) *	1980-12-22	1982-05-18	The Procter & Gamble Company	Anti-arthritic compositions and method using gold salts and organophosphonates
IT1194748B (it) *	1981-02-12	1988-09-28	Gentili Ist Spa	Composizioni farmaceutiche per il trattamento di osteopatie

1982
- 1982-04-15 IT IT8220781A patent/IT1201087B/it active Protection Beyond IP Right Term
1983
- 1983-03-25 CH CH1654/83A patent/CH661437A5/it not_active IP Right Cessation
- 1983-03-30 GB GB08308791A patent/GB2118042B/en not_active Expired
- 1983-04-11 FR FR8305858A patent/FR2525223B1/fr not_active Expired
- 1983-04-13 LU LU84746A patent/LU84746A1/fr active Protection Beyond IP Right Term
- 1983-04-13 JP JP58065160A patent/JPS58189193A/ja active Granted
- 1983-04-13 LU LU88714C patent/LU88714I2/fr unknown
- 1983-04-14 BE BE2/60071A patent/BE896453A/fr not_active IP Right Cessation
- 1983-04-15 NL NL8301324A patent/NL192562C/nl active Protection Beyond IP Right Term
- 1983-04-15 SE SE8302130A patent/SE463239B/sv not_active IP Right Cessation
1984
- 1984-06-08 US US06/618,578 patent/US4621077A/en not_active Expired - Lifetime
1990
- 1990-10-03 HK HK793/90A patent/HK79390A/xx not_active IP Right Cessation
1992
- 1992-06-25 MX MX9203428A patent/MX9203428A/es unknown
1997
- 1997-11-07 NL NL970038C patent/NL970038I2/nl unknown
1998
- 1998-01-09 NL NL980004C patent/NL980004I1/nl unknown
- 1998-01-26 NL NL980005C patent/NL980005I1/nl unknown
- 1998-03-03 NL NL980010C patent/NL980010I1/nl unknown

Also Published As

Publication number	Publication date
IT1201087B (it)	1989-01-27
NL970038I1 (nl)	1998-01-05
SE463239B (sv)	1990-10-29
FR2525223B1 (fr)	1986-04-25
NL980005I1 (nl)	1998-04-01
MX9203428A (es)	1992-07-01
NL192562B (nl)	1997-06-02
JPS58189193A (ja)	1983-11-04
NL8301324A (nl)	1983-11-01
IT8220781A0 (it)	1982-04-15
GB8308791D0 (en)	1983-05-11
BE896453A (fr)	1983-08-01
JPH0213645B2 (it)	1990-04-04
US4621077A (en)	1986-11-04
GB2118042A (en)	1983-10-26
SE8302130D0 (sv)	1983-04-15
LU84746A1 (fr)	1983-11-17
LU88714I2 (fr)	1996-08-23
SE8302130L (sv)	1983-10-16
NL980004I1 (nl)	1998-04-01
HK79390A (en)	1990-10-12
CH661437A5 (it)	1987-07-31
NL980010I1 (nl)	1998-05-06
FR2525223A1 (fr)	1983-10-21
GB2118042B (en)	1986-01-15
NL970038I2 (nl)	2000-11-01

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1987-01-02	BA	A request for search or an international-type search has been filed
1987-01-02	BB	A search report has been drawn up
1987-04-01	BC	A request for examination has been filed
1998-01-05	AC1	Application for a supplementary protection certificate	Free format text: 970038, 971107
1998-04-01	AC1	Application for a supplementary protection certificate	Free format text: 980004, 980109;980005, 980126
1998-05-06	AC1	Application for a supplementary protection certificate	Free format text: 980010, 980303
2000-02-01	SNR	Assignments of patents or rights arising from examined patent applications	Owner name: MSD OVERSEAS MANUFACTURING CO. (IRELAND);MSD OVERS
2000-11-01	KC1	Grant of a supplementary protection certificate	Free format text: 970038, 20030415, EXPIRES: 20080414

Publication	Publication Date	Title
NL192562C (nl)	1997-10-03	Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
DK174744B1 (da)	2003-10-13	(Cycloalkylamino)methylenbis(phosphonsyrer) og farmaceutiske præparater indeholdende forbindelserne
AU726854B2 (en)	2000-11-23	Certain phosphinyl derivatives useful as naaladase inhibitors
JP2859271B2 (ja)	1999-02-17	メチレンホスホノアルキルホスフィネート類、医薬組成物、及び異常カルシウム及びホスフェート代謝の治療方法
US6011021A (en)	2000-01-04	Methods of cancer treatment using naaladase inhibitors
CA2258587A1 (en)	1997-12-24	Hydroxy-phosphinyl derivatives useful as naaladase inhibitors
IL77243A (en)	1996-11-14	Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
JP2001527084A (ja)	2001-12-25	Ｎａａｌｄアーゼ阻害剤のプロドラッグ
KR960001845B1 (ko)	1996-02-06	헤테로사이클 치환된 디포스포네이트 화합물 및 이를 포함하는 약제학적 조성물
AU725455B2 (en)	2000-10-12	Methods of cancer treatment using NAALADase inhibitors
US4578376A (en)	1986-03-25	Pharmaceutical compositions for the treatment of osteopathias
WO1998053812A1 (en)	1998-12-03	Inhibitors of naaladase enzyme activity
KR950009196B1 (ko)	1995-08-16	비사이클릭 디포스포네이트 화합물 및 이를 함유하는 약제학적 조성물
US5990098A (en)	1999-11-23	Therapeutic use of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid and its salts
JP2568999B2 (ja)	1997-01-08	ｇｅｍ−ジホスホネ−トを含有する薬学的組成物
RU2154482C2 (ru)	2000-08-20	Использование пиридилбифосфонатов в качестве терапевтического средства
DE3313049C2 (it)	1991-07-25
MXPA96006180A (en)	1998-01-01	Piridilbisphosphonates to be used as a therapist agent